Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Nasopharyngeal Carcinoma 35Esophageal Squamous Cell Carcinoma 19Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Squamous Cell Carcinoma of Head and Neck 15Triple Negative Breast Neoplasms 14Breast Neoplasms 12Uterine Cervical Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 10Melanoma 10Carcinoma, Renal Cell 9Stomach Neoplasms 8Recurrence 8Head and Neck Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Transitional Cell 5Advanced Solid Tumor 5Urinary Bladder Neoplasms 4Sarcoma 4Pancreatic Neoplasms 4Neoplasms 4Liver Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4Solid Tumor 3Nasopharyngeal Neoplasms 3

Interventions

toripalimab 2zanidatamab 1tislelizumab 1disitamab vedotin 1Probiotics 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Muscle Invasive Bladder Cancer (MIBC) × toripalimab × Clear all
NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
146 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07201675 2025-10-01

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting
59 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡